-
-
-
-
-
-
-
Entera Bio EB613 phase 2 data selected for ASBMR 2026 plenary
-
-
-
-
-
-
-
Rhythm Pharmaceuticals RM-718 shows BMI reduction in Phase 2 trial
-
-
-
-
-
-
-
Candel Therapeutics to present prostate cancer data at ASTRO 2026
-
-
-
-
-
-
-
FDA grants orphan drug status to Zai Lab's zoci for neuroendocrine carcinomas
-
-
-
-
-
-
-
Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
-
-
-
-
-
-
-
Lupin launches generic Sugammadex Injection in the U.S.
-
-
-
-
-
-
-
Aprea expands cancer trial sites and plans Q4 2026 data update
-
76,575 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.

